Yama F Mujadidi
BCA Computer Application , MSc in Information Technology and Software Engineering
Programming and Data Management Director
Automation and Semantic Interoperability in Clinical Trials
Yama F Mujadidi has expertise in the design and development of software and is currently working with Oxford Vaccine Group in the capacity of Clinical Trials IT and Development Lead. He acquired an MSc in Information Technology from University of Bradford United Kingdom, in 2012 after he earned a First class degree in BCA Computer Application from the University of Pune, in the year 2010.
Yama joined Oxford Vaccine Group in June 2013 and tasked to provide specialist advice to research groups to improve quality of clinical trials and to develop an application based on the vaccine knowledge project for use in smart-phones/tablets. Before Oxford Vaccine Group, He had been working with Omni Communication Product Limited as a software developer and contributed to the development of a multi-communication application for use in smartphones and tablets.
Recent publications
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
Journal article
Li G. et al, (2025), Vaccine, 62
-
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
Journal article
Janani L. et al, (2025), J Infect
-
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.
Journal article
Costa Clemens SA. et al, (2025), Mayo Clin Proc Innov Qual Outcomes, 9
-
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern Africa.
Journal article
Chanda C. et al, (2025), Lancet Microbe
-
Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study.
Journal article
Feng S. et al, (2025), J Infect, 90
-
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Journal article
Conlin K. et al, (2025), Vaccine, 45
-
Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia
Preprint
Thindwa D. et al, (2020)